- Home
- HRMY
as 05-09-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 1.6B | IPO Year: | 2020 |
| Target Price: | $52.88 | AVG Volume (30 days): | 701.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.62 | EPS Growth: | 13.13 |
| 52 Week Low/High: | $26.47 - $41.61 | Next Earning Date: | 05-06-2025 |
| Revenue: | $744,852,000 | Revenue Growth: | 20.62% |
| Revenue Growth (this year): | 20.06% | Revenue Growth (next year): | 18.40% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Apr 1 '25 | Sell | $32.80 | 6,987 | $227,385.94 | 740 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Mar 3 '25 | Sell | $32.92 | 4,869 | $159,089.50 | 500 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Harmony Biosciences Holdings First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
3 days ago
Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
Thomson Reuters StreetEvents
3 days ago
Q1 2025 Harmony Biosciences Holdings Inc Earnings Call
Argus Research
3 days ago
HRMY: Raising target price to $42.00
MT Newswires
4 days ago
Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated
Zacks
4 days ago
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
Business Wire
4 days ago
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
GuruFocus.com
5 days ago
Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Report Preview: What to Look For
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.